

INFORMED CONSENT STATEMENT

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 56177

Manuscript Type: *Retrospective study*

Clinical efficacy and analysis of tocilizumab in the treatment of COVID-19: A single center study of 19 Chinese cases

Jia Zeng, Jing Yang, Shengwu Chao, Erli Xu.

Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous data were obtained after each patient agreed to treatment by written consent. And the Diagnosis and Treatment Guidelines of New Coronary Virus Pneumonia (7th Edition) has includes tocilizumab as a recommended drug for immunotherapy in severe patients with COVID-19.

Sincerely,


Erli Xu

Corresponding author: Erli Xu, BD, associate chief physician,
Department of Aviation disease, Naval Medical Center of PLA,
Shanghai City 200052, China. Yijiacheng455@163.com